학술논문

Ruxolitinib in addition to standard of care for the treatment of patients admitted to hospital with COVID-19 (RUXCOVID): a randomised, double-blind, placebo-controlled, phase 3 trial
Document Type
Article
Source
In The Lancet Rheumatology May 2022 4(5):e351-e361
Subject
Primary Research
Articles
Language
ISSN
2665-9913